RU2609412C2 - Композиции, содержащие расщепляемое ферментами пролекарство оксикодона - Google Patents

Композиции, содержащие расщепляемое ферментами пролекарство оксикодона Download PDF

Info

Publication number
RU2609412C2
RU2609412C2 RU2013137452A RU2013137452A RU2609412C2 RU 2609412 C2 RU2609412 C2 RU 2609412C2 RU 2013137452 A RU2013137452 A RU 2013137452A RU 2013137452 A RU2013137452 A RU 2013137452A RU 2609412 C2 RU2609412 C2 RU 2609412C2
Authority
RU
Russia
Prior art keywords
compound
prodrug
trypsin inhibitor
dose
oxycodone
Prior art date
Application number
RU2013137452A
Other languages
English (en)
Russian (ru)
Other versions
RU2013137452A (ru
Inventor
Томас Э. ДЖЕНКИНС
Крэйг О. ХАСФЕЛД
Original Assignee
Сигничер Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигничер Терапьютикс, Инк. filed Critical Сигничер Терапьютикс, Инк.
Publication of RU2013137452A publication Critical patent/RU2013137452A/ru
Application granted granted Critical
Publication of RU2609412C2 publication Critical patent/RU2609412C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2013137452A 2011-01-11 2012-01-09 Композиции, содержащие расщепляемое ферментами пролекарство оксикодона RU2609412C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431781P 2011-01-11 2011-01-11
US61/431,781 2011-01-11
PCT/US2012/020649 WO2012096887A2 (en) 2011-01-11 2012-01-09 Compositions comprising enzyme-cleavable oxycodone prodrug

Publications (2)

Publication Number Publication Date
RU2013137452A RU2013137452A (ru) 2015-02-20
RU2609412C2 true RU2609412C2 (ru) 2017-02-01

Family

ID=46455749

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013137452A RU2609412C2 (ru) 2011-01-11 2012-01-09 Композиции, содержащие расщепляемое ферментами пролекарство оксикодона

Country Status (13)

Country Link
US (3) US8569228B2 (OSRAM)
EP (1) EP2663187B1 (OSRAM)
JP (1) JP6016810B2 (OSRAM)
CN (1) CN103384472B (OSRAM)
AU (1) AU2012205733B2 (OSRAM)
BR (1) BR112013017296B1 (OSRAM)
CA (1) CA2814763C (OSRAM)
DK (1) DK2663187T3 (OSRAM)
ES (1) ES2584634T3 (OSRAM)
IL (1) IL225904B (OSRAM)
RU (1) RU2609412C2 (OSRAM)
TW (1) TWI526209B (OSRAM)
WO (1) WO2012096887A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
BR112012005124B1 (pt) * 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262359A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
BR112013017296B1 (pt) 2011-01-11 2021-02-17 Signature Therapeutics, Inc. composto e composição compreendendo oxicodona, método para reduzir o abuso potencial da referida composição, unidade de dose e método para a sua preparação, e método para identificar um composto e um inibidor de tripsina
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2967424C (en) 2014-11-25 2023-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
EP3555280A4 (en) 2016-12-19 2020-09-09 The Regents of The University of California PEPTIDES SENSITIVE TO TWO ENZYMES
EP3554548A4 (en) 2016-12-19 2020-08-19 The Regents of The University of California NON-CRUSHABLE PILL FORMULATIONS
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2230556C2 (ru) * 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US20070123468A1 (en) * 2005-08-19 2007-05-31 Pharmacofore, Inc. Prodrugs of active agents
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US20100267614A1 (en) * 2007-02-16 2010-10-21 Jenkins Thomas E Prodrugs of Peripheral Phenolic Opioid Antagonists
US20100286186A1 (en) * 2009-04-02 2010-11-11 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
EP0893437A4 (en) 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
WO2000028980A2 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
WO2000036098A1 (en) 1998-12-15 2000-06-22 Tropix, Inc. Multiple enzyme assays
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
EP1161226B1 (en) 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
AU2002316539C1 (en) 2001-06-11 2008-10-30 Medarex, Inc. CD10-activated prodrug compounds
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
EP2319540A1 (en) 2002-02-22 2011-05-11 Shire LLC Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
DE602004024963D1 (de) * 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
NZ544162A (en) 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
NZ546226A (en) 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN101365439B (zh) 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
JP2009533443A (ja) 2006-04-10 2009-09-17 シャイア エルエルシー 一置換及び二置換のオキシコドン化合物及び組成物
US20100144645A1 (en) 2006-04-14 2010-06-10 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
JP5371746B2 (ja) 2006-05-26 2013-12-18 ファーマコフォア， インコーポレイテッド フェノール性オピオイドの制御放出
TWI401237B (zh) 2006-07-24 2013-07-11 ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備
WO2008033980A2 (en) 2006-09-14 2008-03-20 Starfire Systems, Inc. Synthetic process for cyclic organosilanes
US20120142718A1 (en) 2007-02-16 2012-06-07 Jenkins Thomas E N-17-Alkylated Prodrugs of Opioids
KR101607112B1 (ko) 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009080030A1 (en) 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
US20090192095A1 (en) 2008-01-18 2009-07-30 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
EP2252150B1 (en) 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
RU2012105460A (ru) 2009-07-17 2013-08-27 ШАЙЕ ЭлЭлСи Новые карбаматные и пептидные пролекарства опиоидов и их использование
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
BR112012026768A2 (pt) * 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2560491A1 (en) * 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
WO2011133150A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
ES2710617T3 (es) 2010-04-21 2019-04-26 Signature Therapeutics Inc Composiciones que comprenden profármacos de anfetamina escindibles enzimáticamente e inhibidores de los mismos
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262359A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
BR112013017296B1 (pt) * 2011-01-11 2021-02-17 Signature Therapeutics, Inc. composto e composição compreendendo oxicodona, método para reduzir o abuso potencial da referida composição, unidade de dose e método para a sua preparação, e método para identificar um composto e um inibidor de tripsina
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2230556C2 (ru) * 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
US20070123468A1 (en) * 2005-08-19 2007-05-31 Pharmacofore, Inc. Prodrugs of active agents
US20100267614A1 (en) * 2007-02-16 2010-10-21 Jenkins Thomas E Prodrugs of Peripheral Phenolic Opioid Antagonists
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US20100286186A1 (en) * 2009-04-02 2010-11-11 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof

Also Published As

Publication number Publication date
CN103384472A (zh) 2013-11-06
EP2663187B1 (en) 2016-06-01
JP2014502972A (ja) 2014-02-06
US20120178772A1 (en) 2012-07-12
WO2012096887A2 (en) 2012-07-19
BR112013017296A2 (pt) 2017-09-05
BR112013017296B1 (pt) 2021-02-17
HK1189763A1 (zh) 2014-06-20
RU2013137452A (ru) 2015-02-20
ES2584634T3 (es) 2016-09-28
US8569228B2 (en) 2013-10-29
US20150197544A1 (en) 2015-07-16
IL225904B (en) 2020-03-31
US8962547B2 (en) 2015-02-24
CN103384472B (zh) 2016-01-20
AU2012205733B2 (en) 2015-10-08
JP6016810B2 (ja) 2016-10-26
EP2663187A4 (en) 2014-09-10
US20140162935A1 (en) 2014-06-12
WO2012096887A3 (en) 2012-10-04
US9499581B2 (en) 2016-11-22
AU2012205733A1 (en) 2013-05-09
EP2663187A2 (en) 2013-11-20
TWI526209B (zh) 2016-03-21
CA2814763A1 (en) 2012-07-19
CA2814763C (en) 2019-05-28
TW201309297A (zh) 2013-03-01
DK2663187T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
RU2609412C2 (ru) Композиции, содержащие расщепляемое ферментами пролекарство оксикодона
US8497237B2 (en) Compositions comprising enzyme-cleavable oxycodone prodrug
JP6778234B2 (ja) 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
RU2608305C2 (ru) Пролекарства действующих веществ гетероциклическими линкерами
US8685916B2 (en) Opioid prodrugs with heterocyclic linkers
US20130089504A1 (en) Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug
HK1189763B (en) Compositions comprising enzyme-cleavable oxycodone prodrug
HK1193976B (en) Active agent prodrugs with heterocyclic linkers
HK1193976A (en) Active agent prodrugs with heterocyclic linkers
HK1172283B (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof